Is there a need for a pure hypnotic? Approaches to the co-diagnosis of insomnia and anxiety

Journal of Drug Development and Clinical Practice

Volumn 7, Issue 4, 1996, Pages 289-302

  Freeman, H L ^a  

^a 21 Montagu Square ^*  (United Kingdom)

Author keywords

Anxiety; Hypnotics; Insomnia

Indexed keywords

ANXIOLYTIC AGENT; HYPNOTIC AGENT; TRIAZOLAM; ZOLPIDEM; ZOPICLONE;

ANXIETY NEUROSIS; DRUG CHOICE; DRUG EFFICACY; DRUG MONITORING; HUMAN; INSOMNIA; PRESCRIPTION; PRIORITY JOURNAL; REBOUND; REVIEW; SOCIAL PSYCHOLOGY; SYMPTOM;

EID: 0030025234     PISSN: 13579215     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, 1991.
2. Weyerer S, Dilling H. Sleep 1991;14:392-398.
3. National Institutes for Health. JAMA 1984;251:2410-2414.
4. American Sleep Disorders Association. The international classification of sleep disorders: diagnostic and coding manual. Rochester: University of Rochester Press, 1990.
5. Dement WC. J Clin Psychiatry 1992;53:50-56.
6. Mellinger GD, Baiter MB, Uhleshuth EH. Arch Gen Psychiatry 1985;42:225-232.
7. Volrath M, Wicki W, Angst J. Eur Arch Psychiatry Neurol Sei 1989;239:113-124.
8. Post GL, Patrick RO, Crowder JE. J Clin Psychopharmacol 1991:11:249-253.
9. Kales A, Soldâtes CR, Bixler EO, Kales JD. Pharmacology 1983;26:121-137.
10. Fontaine R, Beaudry P, Le Morvan P, Chouinard G. Int Clin Psychopharmacol 1990;5:173-183.
11. Gann H, Reimann D, Hogagen F, et al. J Affect Disord 1992;26:179-189.
12. Joseph KC, Dule D, Sitaram N. Sleep electroencephalo graphie characteristics of anxiety disorder. In: Kryger MH, Roth T, Dement WC, editors. Principles of practice of sleep medicine. Philadelphia: Saunders, 1989.
13. Abramson L, Keshaven MS, Sitaram N. Biol Psychiatry 1989;26:496-499.
14. Stein MB, Kroft CDL, Walker JR. Pyschiatry Res 1993;49:251-256.
15. Stein MB, Kroft CDL, Chartier M, Walker JR. Sleep in nondepressed patients with panic disorder. I. Systematic assessment of sleep architecture and sleep continuity. Sleep 1994. In press.
16. Hall MH, Dahl RE, Dew MA, Reynolds CF. Directions in Psychiatry 1995;15(9):l-7.
17. Hudson Jl, Pope HG, Sullivan LE, et al. Biol Psychiatry 1992;32:958-975.
18. Dement WC. Rational basis for the use of sleeping pills. Pharmacology 1983;72 Suppl 2:3-28.
19. Morgan K. Drugs 1990;10:688-96.
20. Balter MB, Bauer ML. Patterns of prescribing and use of hypnotic drugs in the United States. In: Clift AD, editor. Sleep disturbance and hypnotic drug dependence. Amsterdam: Excerpta Medica, 1975.
21. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Eur Neuropsychopharmacol 1992;2:167-169.
22. Bliwise DL, King AB, Harris RB, Haskell WL. Soc Sei Med 1992;34:49-55.
23. Prinz PN, Vitiello MV, Raskind MA. N Engl J Med 1990:323:520-526.
24. Shapiro CM, Dement WC. Br Med J 1993;306:1604-1607.
25. Roth T, Kramer M, Lutz T. Drugs Exp Clin Res 1977:1:271-277.
26. Greenblatt DJ, Miller LG, Shader RI. Psychiatr Res 1990;24 Suppl 2:73-79.
27. Lader MH. Abuse potential, tolerance and dependence on chronic anxiolytic treatment. In: Mendlewicz J, Ralogni G, editors. Target receptors for anxiolytics and hypnotics:from molecular pharmacology1 to therapeutics. Basel: Karger, 1995.
28. Nicholson AN, Pascoe DA. Br J Pharmacol 1986:21:205-211.
29. GillinJC, Spinweber GL, Johnson LC.J Clin Psychopharmacol 19S9;2:161-172.
30. Merlotti L, Roehrs T, Zorick FJ, Roth T. J Clin Psychopharmacol 1991:11:368-373.
31. Roehrs T, Zorick F, Witty R. Br J Clin Pharmacol 1986;22:143-147.
32. O'DonovanMC, McGuffin P. BrMed J 1993:306:945-946.
33. Malpas A, Legg NJ, Scott DE Br J Psychiatry' 1974;124:48284.
34. Morgan K, Dallosso H, Ebrahim S, et al. Br Med J 198S;296:601-602.
35. Rumble R, Morgan K.J Am GeriatrSoc 1992;40:787-791.
36. Blanchard JC, Zundel JL, Julau L. Biochcm Pharmacol 1983;32:3651-3653.
37. Trifiletti RR, Snyder SH. Mol Pharmacol 1984;26:458-469.
38. Goa KL, Heel RC. Zopliconc. Drug 1986;32:48-65.
39. Hallstrom CO. Zopiclone. Prescribe'J 1994;34:115-119.
40. Kerr JS, Dawe RA, Parkin C, Hindmarch I. Hum Psychopharmacol 1995;10:221-229.
41. Langer SZ, Arbilla S, Scatton. Receptors involved in the mechanism of action of zolpidem. In: Imidazopyridines in sleep disorders. Sauvanet JP, Langer SZ, Morselli PL, editors. New York: Raven Press, 1988:55-70.
42. Costa E, Puia G, Vicini S. Impact of current developments in molecular biology on the pharmacotherapy of anxiety disorders. In: Meltzer D, Nerozzi D, editors. Current practices and future developments in the pharmacotherapy of mental disorders. Amsterdam: Elsevier, 1995.
43. Langer SZ, Arbilla S. Pharmacol Biochem Behav 1988;29:763-766.
44. Thenot JP, Hermann P, Durand A. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL. editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988:139.
45. Langtry SZ, Benfield P. Drugs 1990;40:291-313.
46. Ansseau M, Pitchot W, Hansenne M, Motero AG. Lancet 1992;339:809.
47. Haefely W, Facklam M, Schoch P. Adv Biochem Psychopharmacol 1992;47:379-394.